Objective Every 40 seconds, someone in Europe suffers from a stroke killing 1,000 Europeans daily. The resulting economic damage is immense. In the 2006 wake-up-study funded by the EU the economic damage in Europe amounts to 36 billion EUR per year. The objective of this project is the clinical validation of SoNovum AG’s UltraEASY™ II Brain Vitals Monitoring System and the underlying CAMUD technology for diagnosing and monitoring neuropathologies in acute events and at-risk patient groups. CAMUD stands for “Computer Aided Multispectral Ultrasound Diagnostics” and is a novel diagnostic method based on molecular acoustics. It measures the feedback of ultrasound waves on multiple frequencies, which is interpretable for the first time thanks to modern computer technology. The technology enables, among other things, a fast, very precise and non-invasive diagnosis of the brain tissue in the beginning of the therapeutic time frame as well as further, continuous monitoring. Therewith physicians will be able to diagnose acute events more quickly and preventatively at-risk patient groups, even before harmful incidents occur. Initial target market groups for UltraEASY II include the stroke units in clinics as well as family and specialist's practices in Europe with regard to global markets as well. Because of high mobility, flexibility and the small acquisition costs, it is well suited as basic equipment for practices as well as, in its mobile version, for helicopters, rescue vehicles and ambulances of clinics and emergency organizations. The objectives of this Feasibility Study are the examination of the market acceptance towards UltraEASY II, addressing clinics and physicians as well as involving patients, patient organizations and health insurance carriers, in order to conduct the risk evaluation for the final realization of the CAMUD technology in the MedTech sector and conclude the development of final innovation strategies for Phase 2. Fields of science medical and health sciencesclinical medicinephysiotherapyengineering and technologymechanical engineeringvehicle engineeringaerospace engineeringaircraftrotorcraftmedical and health sciencesbasic medicineneurologystrokenatural sciencesphysical sciencesacousticsultrasound Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2015 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SONOVUM AG Net EU contribution € 50 000,00 Address PERLICKSTRASSE 5 04103 LEIPZIG Germany See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Sachsen Leipzig Leipzig Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00